Pages that link to "Q36539266"
Jump to navigation
Jump to search
The following pages link to Consensus report of the international society of gastrointestinal oncology on therapeutic progress in advanced pancreatic cancer (Q36539266):
Displaying 29 items.
- Baicalein, a component of Scutellaria baicalensis, induces apoptosis by Mcl-1 down-regulation in human pancreatic cancer cells (Q24604942) (← links)
- A Phase II study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) and gemcitabine in advanced pancreatic carcinoma. A trial of the Princess Margaret hospital Phase II consortium (Q33375650) (← links)
- Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205 (Q34049250) (← links)
- Progress for resectable pancreatic [corrected] cancer?: a population-based assessment of US practices (Q34097755) (← links)
- Single-nucleotide polymorphisms of DNA damage response genes are associated with overall survival in patients with pancreatic cancer (Q34766691) (← links)
- Cyclooxygenase-2 Confers Growth Advantage to Syngeneic Pancreatic Cancer Cells (Q34802656) (← links)
- Simultaneous knock-down of Bcl-xL and Mcl-1 induces apoptosis through Bax activation in pancreatic cancer cells (Q34953963) (← links)
- Inoperable pancreatic cancer patients who have prolonged survival exhibit an increased risk of cholangitis (Q36020628) (← links)
- Erlotinib plus gemcitabine versus gemcitabine for pancreatic cancer: real-world analysis of Korean national database (Q36072863) (← links)
- Oxaliplatin and Bolus-Modulated 5-Fluorouracil as a Second-Line Treatment for Advanced Pancreatic Cancer: Can Bolus Regimens Replace FOLFOX When Considered for Second Line? (Q36682682) (← links)
- Molecular mechanisms of pancreatic cancer and potential targets of treatment (Q36758436) (← links)
- Medical treatment of pancreatic cancer (Q36788494) (← links)
- The role of second-line chemotherapy after gemcitabine failure in patients with advanced pancreatic cancer (Q37074126) (← links)
- The molecular biology of pancreatic cancer (Q37153303) (← links)
- Clinical importance of B7-H3 expression in human pancreatic cancer (Q37424100) (← links)
- Chemoradiotherapy with concurrent gemcitabine and cisplatin with or without sequential chemotherapy with gemcitabine/cisplatin vs chemoradiotherapy with concurrent 5-fluorouracil in patients with locally advanced pancreatic cancer--a multi-centre ra (Q37457763) (← links)
- Accomplishments in 2008 in the treatment of metastatic pancreatic cancer. (Q37468871) (← links)
- Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB). (Q37569035) (← links)
- Management of advanced pancreatic cancer (Q37960190) (← links)
- Baicalein--an intriguing therapeutic phytochemical in pancreatic cancer (Q38058846) (← links)
- Interaction of tumour cells with their microenvironment: ion channels and cell adhesion molecules. A focus on pancreatic cancer (Q38184985) (← links)
- Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial (Q38996447) (← links)
- Endoscopic ultrasound delivery of an antitumor agent to treat a case of pancreatic cancer (Q39324152) (← links)
- Tumor specific low pH environments enhance the cytotoxicity of lovastatin and cantharidin (Q39657136) (← links)
- Advanced pancreatic cancer: the use of the apparent diffusion coefficient to predict response to chemotherapy (Q46190697) (← links)
- Gemcitabine combined with gefitinib in patients with inoperable or metastatic pancreatic cancer: a phase II Study of the Hellenic Cooperative Oncology Group with biomarker evaluation (Q46362755) (← links)
- Alterations in Pharmacokinetics of Gemcitabine and Erlotinib by Concurrent Administration of Hyangsayukgunja-Tang, a Gastroprotective Herbal Medicine. (Q48004181) (← links)
- Circulating nucleosomes and immunogenic cell death markers HMGB1, sRAGE and DNAse in patients with advanced pancreatic cancer undergoing chemotherapy (Q50943644) (← links)
- Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma (Q80595806) (← links)